Blinatumomab Biosimilar - Research Grade

Blinatumomab Biosimilar - Research Grade, His

Target: CD3/CD19.

Specificity: Detects human CD3/CD19. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Blinatumomab.

Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Background: Blinatumomab is a bispecific T-cell engager (BiTE). It enables a patient’s T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells.

Concentration: 5mg/ml.

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE.

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

• Artikelnummer: ICH5025-0.5MG
• Hersteller: Ichorbio
• Hersteller Artikelnummer: ICH5025-0.5MG
• Verpackungseinheit: 0.5mg
• Mengeneinheit: STK
• Reaktivität: Human
• Klonalität: Monoclonal
• Methode: Functional Assay
• Isotyp: His